First Cystic Fibrosis Drugs To Target Underlying Genetic Defect Are In Phase II
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The first cystic fibrosis drugs to mitigate the ion transport defect underlying the disease are in Phase II, with the support of the Cystic Fibrosis Foundation’s extensive therapeutics development program.